Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathol...

Descripción completa

Detalles Bibliográficos
Autores principales: Milà-Alomà, Marta, Ashton, Nicholas J., Shekari, Mahnaz, Salvadó, Gemma, Ortiz-Romero, Paula, Montoliu-Gaya, Laia, Benedet, Andrea L., Karikari, Thomas K., Lantero-Rodriguez, Juan, Vanmechelen, Eugeen, Day, Theresa A., González-Escalante, Armand, Sánchez-Benavides, Gonzalo, Minguillon, Carolina, Fauria, Karine, Molinuevo, José Luis, Dage, Jeffrey L., Zetterberg, Henrik, Gispert, Juan Domingo, Suárez-Calvet, Marc, Blennow, Kaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499867/
https://www.ncbi.nlm.nih.gov/pubmed/35953717
http://dx.doi.org/10.1038/s41591-022-01925-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499867/
https://www.ncbi.nlm.nih.gov/pubmed/35953717
http://dx.doi.org/10.1038/s41591-022-01925-w

Ejemplares similares